Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

Financials ($)
Sales 2016 11 094 M
EBIT 2016 3 163 M
Net income 2016 2 079 M
Debt 2016 11 512 M
Yield 2016 -
Sales 2017 13 004 M
EBIT 2017 3 884 M
Net income 2017 2 586 M
Debt 2017 11 153 M
Yield 2017 -
P/E ratio 2016 16,61
P/E ratio 2017 9,41
EV / Sales2016 2,90x
EV / Sales2017 2,45x
Capitalization 20 690 M
More Financials
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted primarily in the U.S. and... 
11/09Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
07:27p MYLAN : Launches First Generics of Benicar® and Benicar HCT® Tablets
07:04p MYLAN : EpiPen Maker Mylan Hit With Class-Action Lawsuit
10/25 Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 Fr..
10/21 Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in My..
10/20 MYL NOTICE : Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline i..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/14 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Mylan N.V. In..
10/13 BERNSTEIN LIEBHARD LLP : Announces That A Suit Has Been Filed Against Mylan, N.V..
10/12 Investigation of Mylan N.V. Announced by Law Offices of Howard G. Smith
10/11 Rosen Law Firm Files Securities Class Action Lawsuit Against Mylan N.V. - MYL
More news
Sector news : Pharmaceuticals - NEC
04:13p GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
04:05pDJGlaxo Profit Jumps on Weaker Pound
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 53,2 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%20 690
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results